Cimicifugol
CAS No. 3779-59-7
Cimicifugol( ——— )
Catalog No. M38813 CAS No. 3779-59-7
Cimigenol is an active compound isolated from Cimicifuga, with potent anti-tumor activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 666 | In Stock |
|
| 25MG | Get Quote | In Stock |
|
| 50MG | Get Quote | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCimicifugol
-
NoteResearch use only, not for human use.
-
Brief DescriptionCimigenol is an active compound isolated from Cimicifuga, with potent anti-tumor activity.
-
DescriptionCimigenol is a potential antitumor compound, combination of it with an autophagy inhibitor may be a valuable strategy for the chemoprevention or treatment of colon cancer.
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number3779-59-7
-
Formula Weight488.709
-
Molecular FormulaC30H48O5
-
Purity>98% (HPLC)
-
SolubilityDMSO : 100 mg/mL (204.62 mM; ultraphonic )
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Hydroxocobalamin
Hydroxocobalamin (Standard) is the analytical standard of Hydroxocobalamin. This product is intended for research and analytical applications. Hydroxocobalamin (Vitamin B12a) is an injectable naturally occurring form of vitamin B12 with a favorable adverse effect profile, used as a dietary supplement in the treatment of vitamin B12 deficiency including pernicious anemia.
-
Trastuzumab deruxtec...
Trastuzumab deruxtecan (T-DXd) is an antibody-active molecule conjugate (ADC) with anticancer and antitumor activity, which is composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2) coupled to a topoisomerase I inhibitor (DXd).
-
BDA 366
BDA-366 specifically targets the BH4 domain of Bcl2 BDA-366 and suppresses human myeloma growth. BDA-366 induces robust apoptosis in MM cell lines and primary MM cells by inducing BCL2 conformational change.
Cart
sales@molnova.com